Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ZIOP

ZIOPHARM Oncology (ZIOP) Stock Price, News & Analysis

ZIOPHARM Oncology logo

About ZIOPHARM Oncology Stock (NASDAQ:ZIOP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.82
$1.39
52-Week Range
N/A
Volume
2.13 million shs
Average Volume
2.01 million shs
Market Capitalization
$187.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ZIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZIOP Stock News Headlines

Best Global Universities for Oncology
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it could transform warfare, robotics, and the global economy. But you don’t need to buy Tesla or wait for xAI to IPO to benefit. One overlooked public company is supplying the critical tech behind Musk’s AI push — and it trades for a fraction of Nvidia’s price. Hedge funds are already loading up, but most investors haven’t noticed yet.tc pixel
Alx Oncology Holdings (ALXO)
CG Oncology Inc
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
WBSPH 2024 - Oncology
See More Headlines

ZIOP Stock Analysis - Frequently Asked Questions

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. The biotechnology company earned $0.40 million during the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that ZIOPHARM Oncology investors own include Precigen (PGEN), Bristol Myers Squibb (BMY), OPKO Health (OPK), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Amarin (AMRN) and CorMedix (CRMD).

Company Calendar

Last Earnings
11/08/2021
Today
9/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZIOP
CIK
1107421
Employees
105
Year Founded
2005

Profitability

EPS (Trailing Twelve Months)
($0.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$79.98 million
Net Margins
N/A
Pretax Margin
-22,544.97%
Return on Equity
-92.84%
Return on Assets
-72.46%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
3.43
Quick Ratio
3.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.58 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
216,146,000
Free Float
204,906,000
Market Cap
$187.12 million
Optionable
Optionable
Beta
1.71

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ZIOP) was last updated on 9/1/2025 by MarketBeat.com Staff
From Our Partners